







<u>Jintanat Ananworanich</u>, Alexandra Schuetz, Claire Deleage, Irini Sereti, Suteeraporn Pinyakorn, Rungsun Rerknimitr, James LK Fletcher, Yuwadee Phuang-Ngern, Duanghathai Suttichom, Bonnie Slike, Mary Marovich, Robin dewar, Merlin L Robb, Jerome H Kim, Mark de Souza, Jacob Estes on behalf of the **RV254/SEARCH 010 Study Group**

Background

- Lamina propria (LP) CD4 T cells are depleted early in HIV infection
 - setting the stage for ongoing immune activation and CD4 depletion in chronic infection
- Timing of LP CD4 depletion and factors contributing to this depletion in early acute HIV is not well understood
- Objective

 Investigate LP CD4 depletion during acute HIV infection

Brenchley JM, JEM 2004; Mehandru S, Plos Med 2006



Methods

- Prospective screening and enrollment of acutely HIVinfected subjects in Bangkok, Thailand
 - Enrollment of HIV-uninfected and untreated chronically infected Thais as controls
- Peripheral blood (PB): CD4, HIV RNA, inflammatory biomarkers
 - sCD14, LPS, IFABP, D-dimer, HA, CRP, IL6
 TNFa, TNF-RII, MCP, IP10, neopterin
- Sigmoid colon biopsy
 - Flow cytometry for total gut %CD4
 and %activated CD4 and CD8+ T cells (MMC)
 - Gut HIV RNA



Immunohistochemistry (IHC) and Image Analysis for LP CD4%



Baseline Characteristics

Values (median)	Acute HIV	Chronic HIV	HIV uninfected			
Ν	38	5	10			
Age, years	28	24	31			
%male	92%	100%	80%			
HIV-related characteristics						
PB CD4, cells/mm ³	437	515	Not applicable			
PB HIV RNA, log ₁₀ copies/ml	5.5	4.9				
Gut HIV RNA, log ₁₀ copies/mg tissue	2.8	Not done				
CRF01_AE	83%	Not done				

Baseline Characteristics: Acute HIV Infection

AHI staging	Fiebig I	Fiebig II	Fiebig III	Fiebig IV/V
Laboratory testing	RNA+, p24-, IgM-	RNA+, p24+ , IgM-	IgM+ , IgG-, WB-	lgG -/+ WB IND/ + without p31
Ν	12	4	18	4
PB CD4, cells/mm ³	560	348	388*	362
PB HIVRNA, log ₁₀ copies/ml	4.3	6.0*	5.6*	5.9*
Gut HIVRNA, log ₁₀ copies/mg tissue	1.7	2.88	3.1*	2.9*

*p < 0.05

Decreases in LP CD4 in Fiebig 3 compared to Fiebig I and HIV- control

CD4+T cells/Myeloid cells



HIV- Control

Fiebig 1

Fiebig 3

Lamina Propria CD4 by IHC



Flow cytometry (MMC) Gut T cell activation during acute HIV infection



CD4+HLADR+38+

CD8+HLADR+38+

* p < 0.05 compared to HIV-control

Decreases of LP CD4 T cells correlated with colonic mucosal T cell activation



CD4+HLADR+38+

CD8+HLADR+38+

Similar inverse correlations are observed with activated T cells in peripheral blood

Levels of Plasma Biomarkers by Fiebig stage



Decreases of LP CD4 T cells correlated with higher plasma biomarkers levels



Decreases of LP CD4 T cells correlated with high HIV RNA in blood and sigmoid colon



Blood

Sigmoid colon

What happens to lamina propria CD4 after ART?

At month 6

All patients had HIV RNA < 50 copies/ml in blood HIV RNA < 50 copies/mg tissue of sigmoid colon

No reconstitution of Iamina propria CD4+ T cells after 6 months of ART



Summary

- Significant depletion of sigmoid LP CD4 T cells occurs after Fiebig I and is associated with
 - Plasma inflammatory biomarkers
 - T cell activation and HIV viremia in blood and gut
- No short-term reconstitution of LP CD4 T cells after ART

Discussion

- Timing of LP CD4 depletion and its association with immune activation is consistent with the SIV literature^{1,2,3}
- In humans, significant gut CD4 depletion and immune activation occur in chronic HIV and persist after ART^{4,5}
- Available data from later acutely infected subjects (Fiebig IV+)
 - LP CD4 is depleted with partial reconstitution after ART^{6,7}
 - Gut Th17 depletion⁸ and altered homing receptors⁹ are associated with CD4 depletion and immune activation. Numbers but not function of Th17 is rapidly restored after ART.¹⁰
- Strength and weaknesses of our study
 - Population of early acutely infected subjects particularly Fiebig I
 - Small sample size and small pieces of gut tissue from sigmoid colon only. Analysis has not yet included other important parameters

¹Estes DJ, Plos Pathogens 2010; ²Tabb B, JID 2013; ³Ortiz AM, JCI 2011; ⁴Ciccone EJ, Mucosal Immunol 2010; ⁵Gordon SN, JI 2010; ⁶Mehandru S, Plos Med 2006; ⁷Guadalupe M, JV 2003; ⁸Kim CJ, JI 2013 ; ⁹Mavigner M, JCI 2012

Clinical Implications and future studies

- Fiebig I acute HIV infection may be a window of opportunity to intervene before significant gut CD4 depletion and immune activation occurs
- However short-term LP CD4 reconstitution after ART is not seen
 - Persistent LP CD4 depletion is seen in long-term treated acutely infected patients¹
 - Clinical consequence is not well understood
- Future studies
 - Longer term follow up after ART of LP CD4, Th17 and other relevant cell types, gut epithelial disruption and immune activation

SEARCH 010/RV254 Acknowledgement Volunteers Funding: US MHRP, NIH, amfAR

AFRIMS

- o Robert O'Connell
- o Alexandra Schuetz
- Rapee Trichavaroj
- o Vatcharain Assawadarachai
- Yuwadee Phuangngern
- o Wiriya Rutvisuttinunt
- Nantana Tantibul
- Panadda Sawangsinth
- o Susan Mason
- Bessara Nuntapinit
- o Siriwat Akapirat
- Wanwarang Khobchit
- Sakuna Suksawad
- o Ajchariyarat Sangdara
- Kultida Poltavee
- Hathairat Savadsuk
- Suwittra Chaemchuen
- Surat Jongrakthaitae
- o Chayada Sajiaweerawan
- Nipattra Tragonlugsana

WRAIR/MHRP

- o Nelson Michael
- o Jerome Kim
- o Merlin Robb
- o Hendrik Streeck
- o Diane Bolton
- o Bonnie Slike
- Sodsai Tovanabutra
- Gustavo Kijak

Chulalongkorn

- Kiat Ruxrungtham
- o Rungsun Rerknimitr
- o Wiriyaporn Ridtitid
- Sukalya Lerdlum
- o Mantana pothisri
- Phandee Wattanaboonyongcharoen
- o Ponlapat Rojnuckarin
- Sopark Manasnayakorn
- o Sunee Sirivichayakul
- Supranee Buranapraditkun

NIAID/NCI

- o Irini Sereti
- o Daniel Douek
- o Netanya Sandler
- o Mary Marovich
- Jacob Estes
- o Claire Deleage
- o Robin Dewar
- Adam Rupert

SAIC-Frederick

- o Frank Maldarelli
- Mary Kearney
- Ann Wiggins

VGTI

- Nicolas Chomont
- Rafick Sekaly
- Elias Haddad
- Lydie Trautmann

Thai Red Cross AIDS Res Center

- o Praphan Phanuphak
- o Nittaya Phanuphak
- o Mark de Souza
- Frits van Griensven
- o Thep Chalermchai
- o James Fletcher
- o Eugene Kroon
- Nipat Teeratakulpisarn
- Nitiya Chomchey
- o Duanghathai Suttichom
- o Somprartthana Rattanamanee
- o Peeraya Mungu
- Suteeraporn Pinyakorn
- o Putthachard Saengtawan
- Sasiwimol Ubolyam
- o Tippawan Pankam

UCSF

Victor Valcour

Yale

- Serena Spudich
- o Idil Kore

Industry

- Thai GPO (TDF, 3TC, EFV, LPV/r)
- o Gilead (TDF, FTC, Atripla)
- Merck (EEV, RAL)
- Pfizer (MVC)
- Monogram (Trofile)